Shots:

• The FDA’s FT designation follows P-I/II study assessing AMT-130 in patients with Huntington’s disease with an expected initiation in H2’19
• FDA grant Fast Track designation to facilitate the development & and expedite the review of drugs to treat serious conditions and fill an unmet medical need
• AMT-130 is an AVV5 gene therapy one-time administered carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein and targets highly toxic exon1 protein fragment 

Ref: uniQure | Image: Twitter